



This is a repository copy of *Implications of confirmed de novo pathogenic SOD1 mutations.*

White Rose Research Online URL for this paper:  
<https://eprints.whiterose.ac.uk/178910/>

Version: Accepted Version

---

**Article:**

Cooper-Knock, J. [orcid.org/0000-0002-0873-8689](https://orcid.org/0000-0002-0873-8689) (2022) Implications of confirmed de novo pathogenic SOD1 mutations. *Journal of Neurology, Neurosurgery and Psychiatry*, 93 (2). 118. ISSN 0022-3050

<https://doi.org/10.1136/jnnp-2021-327935>

---

This article has been accepted for publication in *Journal of Neurology, Neurosurgery and Psychiatry*, 2021 following peer review, and the Version of Record can be accessed online at <http://dx.doi.org/10.1136/jnnp-2021-327935>. © Authors (or their employer(s)) 2021. Reuse of this manuscript version (excluding any databases, tables, diagrams, photographs and other images or illustrative material included where a another copyright owner is identified) is permitted strictly pursuant to the terms of the Creative Commons Attribution-Non Commercial 4.0 International (CC-BY-NC 4.0) <https://creativecommons.org/licenses/by-nc/4.0/>

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new works must also acknowledge the authors and be non-commercial. You don't have to license any derivative works on the same terms. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

Journal of  
**Neurology, Neurosurgery  
& Psychiatry**

**Implications of confirmed de novo pathogenic SOD1  
mutations**

Journal:	<i>Journal of Neurology, Neurosurgery, and Psychiatry</i>
Manuscript ID	jnnp-2021-327935.R1
Article Type:	Editorial commentary
Date Submitted by the Author:	21-Sep-2021
Complete List of Authors:	Cooper-Knock, Johnathan; The University of Sheffield Institute for Translational Neuroscience, Neurology
<b>Specialty</b> :	Neurodegenerative
Keywords:	MOTOR NEURON DISEASE, GENETICS

SCHOLARONE™  
Manuscripts

## Implications of confirmed *de novo* pathogenic SOD1 mutations

Johnathan Cooper-Knock<sup>1</sup>

<sup>1</sup>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield,  
Sheffield, UK

Correspondence should be addressed to JCK (j.cooper-knock@sheffield.ac.uk)

Dr Johnathan Cooper-Knock,  
Sheffield Institute for Translational Neuroscience.  
385 Glossop Road,  
Sheffield S10 2HQ,  
United Kingdom.

1  
2  
3 **Leading sentence:** The implications of confirmed *de novo* pathogenic mutations in  
4 SOD1 are far-reaching for current clinical practice and future genetic research.  
5  
6  
7  
8  
9

10 Progress has been made in the study of ALS genetics in recent years but there  
11 remains debate regarding the role of mutations which develop *de novo* in a patient,  
12 rather than being inherited from one or both parents. Theoretically such mutations  
13 should occur but relatively few are reported. The mutation rate is estimated at  $1.8 \times 10^{-8}$   
14 per nucleotide per generation [1], and therefore all individuals must carry *de novo*  
15 genetic changes. Moreover, ALS-associated mutations are not embryonically lethal  
16 and so there is no obvious reason why *de novo* forms of such mutations should not be  
17 present in ALS patients. Occurrence of *de novo* mutations could explain minimal or  
18 even absent family history for patients carrying mutations which otherwise behave in  
19 a monogenic fashion. Such observations are often attributed to 'variable penetrance'  
20 which has led to a search for therapeutic targets to reduce penetrance.  
21  
22  
23  
24  
25  
26  
27  
28  
29

30 Conversely, if penetrance is actually 100%, but sporadic instances of monogenic  
31 disease are the result of *de novo* changes, then searching for therapeutic modifiers  
32 may prove futile. To differentiate between these two alternatives requires genetic  
33 profiling of patients and their biological parents to demonstrate that a candidate *de*  
34 *nov* mutation is not inherited. That is exactly what Müller and colleagues have  
35 achieved in their study published in this issue of the journal [2]. By sequencing 4,100  
36 sporadic ALS patients and their parents, the authors discovered four instances of  
37 mutations within SOD1 which were absent from both parents. They took important  
38 steps to be sure that the correct biological parents had been sequenced. Moreover, in  
39 each case, the reported SOD1 mutations had been previously reported in familial  
40 SOD1-ALS and co-segregation with disease confirmed: this helps to overcome any  
41 doubts about the validity of the changes observed.  
42  
43  
44  
45  
46  
47  
48  
49  
50

51 The authors extended their work with evidence for mutational hot-spots within the  
52 SOD1 gene associated with codons Ala5 and Asp102. This was based on observed  
53 clusters of mutations associated with limited or absent family history which had arisen  
54 in multiple population groups. This is contrasted with other mutations, such as  
55 p.Asp91Ala, where a common founder is postulated based on haplotype analysis. This  
56 important observation will help the search for further *de novo* mutations.  
57  
58  
59  
60

1  
2  
3 The study by Muller and colleagues addresses the issue of somatic mosaicism which  
4 is linked to *de novo* mutations. Presumably the patients described in this report were  
5 the product of germline mutations, although it remains plausible that similar *de novo*  
6 mutations could occur at any stage of nervous system development. ALS is a nervous  
7 system-specific disease and as a result, a mutation may cause disease and still be  
8 absent from peripheral blood, which is the usual source of DNA for routine diagnostic  
9 screening. To uncover the role of such somatic mutations will require substantial  
10 investment to sequence not only multiple individuals but also multiple tissues. This  
11 work lays the foundation for such a study. It is possible that somatic mutations play a  
12 role in the apparent disparity between broad-sense heritability for ALS which is  
13 measured at ~50%, and the much smaller (<10%) SNP-based heritability [3] measured  
14 from peripheral blood.

15  
16  
17 Finally, the authors point out the important clinical implications of their observations. If  
18 *de novo* mutations are a significant cause of apparently sporadic ALS, then clinicians  
19 will only detect these patients through routine genetic screening rather than confining  
20 screening to patients with a family history of disease [4]. In an age where gene therapy  
21 for SOD1-ALS is a reality, this is a pertinent truth [5].

22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35 **Acknowledgement:** This work was supported by Wellcome Trust (216596/Z/19/Z).

### 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

**References:**

- 1 Kondrashov AS. Direct estimates of human per nucleotide mutation rates at 20 loci causing Mendelian diseases. *Hum Mutat* 2003;21:12–27.
- 2 Müller K, Oh K-W, Nordin A, *et al.* De novo mutations in SOD1 is a cause of ALS. *J Neurol Neurosurg Psychiatry* In Press.
- 3 Cooper-Knock J, Harvey C, Zhang S, *et al.* Advances in the genetic classification of amyotrophic lateral sclerosis. *Curr Opin Neurol* Published Online First: 2 August 2021. doi:10.1097/WCO.0000000000000986
- 4 Shephard SR, Parker MD, Cooper-Knock J, *et al.* Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. *J Neurol Neurosurg Psychiatry* Published Online First: 14 February 2021. doi:10.1136/jnnp-2020-325014
- 5 Miller T, Cudkovicz M, Shaw PJ, *et al.* Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. *N Engl J Med* 2020;383:109–19.